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Background: XB130 has been reported to be expressed by various types of cells such as thyroid cancer and
esophageal cancer cells, and it promotes the proliferation and invasion of thyroid cancer cells. Our previous study
demonstrated that XB130 is also expressed in gastric cancer (GC), and that its expression is associated with the
prognosis, but the role of XB130 in GC has not been well characterized.
Methods: In this study, we investigated the influence of XB130 on gastric tumorigenesis and metastasis in vivo and
in vitro using the MTT assay, clonogenic assay, BrdU incorporation assay, 3D culture, immunohistochemistry and
immunofluorescence. Western blot analysis was also performed to identify the potential mechanisms involved.
Results: The proliferation, migration, and invasion of SGC7901 and MNK45 gastric adenocarcinoma cell lines were
all significantly inhibited by knockdown of XB130 using small hairpin RNA. In a xenograft model, tumor growth was
markedly inhibited after shXB130-transfected GC cells were implanted into nude mice. After XB130 knockdown,
GC cells showed a more epithelial-like phenotype, suggesting an inhibition of the epithelial-mesenchymal transition
(EMT) process. In addition, silencing of XB130 reduced the expression of p-Akt/Akt, upregulated expression of
epithelial markers including E-cadherin, α-catenin and β-catenin, and downregulated mesenchymal markers including
fibronectin and vimentin. Expression of oncoproteins related to tumor metastasis, such as MMP2, MMP9, and CD44,
was also significantly reduced.
Conclusions: These findings indicate that XB130 enhances cell motility and invasiveness by modulating the EMT-like
process, while silencing XB130 in GC suppresses tumorigenesis and metastasis, suggesting that it may be a potential
therapeutic target.
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XB130 is a newly identified adaptor protein that is
expressed in the spleen, thyroid, and esophagus in humans
[1,2]. It has also been detected in follicular and papillary
thyroid carcinoma cell lines [3]. As a tumor promoter,
XB130 has been found to enhance cell proliferation,
metastasis, and resistance to cell death, as well as being
involved in signal transduction in thyroid cancer cells [3].
Our previous study revealed that XB130 is expressed in
gastric cancer (GC) and that its expression can predict the
survival prognosis and chemotherapeutic-sensitivity [4],* Correspondence: nfyyzq@126.com; nfyyliaowj@163.com
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reproduction in any medium, provided the orsuggesting that XB130 plays an important role in GC.
However, the detailed mechanisms by which XB130 acts
in GC remain poorly defined.
As a member of the actin filament-associated protein
(AFAP) family of adaptor proteins, XB130 has been
reported to display a high affinity for lamellipodial
(branched) F-actin and to influence thyroid cancer cell
motility and invasiveness [5]. Lamellipodia are essential
for the formation of migratory membrane protrusions, an
event that is closely related to the epithelial-mesenchymal
transition (EMT). The EMT is the process by which
epithelial cells undergo a phenotypic change to become
mesenchymal cells and it is a key step in tumor invasion
and metastasis [6]. Several signaling pathways are involved in
this process, including those mediated by focal adhesion. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and mitogen-activated protein kinase (MAPK) [7-9].
It has been showed that XB130 is involved in the activation
of Akt [10,11], while Xu et al. demonstrated that
XB130 participates in activation of the c-Src pathway
[1]. Intriguingly, these signaling pathways have been
reported to play an essential role in the development
and progression of GC [12-14], suggesting that XB130
could also be a pro-metastatic factor for GC. However,
whether XB130 is involved in promoting the EMT process
and metastasis of GC remains undetermined.
In the present study, we used XB130-silenced cell lines
that we established in previous study [4] to investigate
the influence of XB130 on GC both in vitro and in vivo.
Our hypothesis was that XB130 would promote GC
proliferation and invasion, as well as having a role in
the EMT.
Methods
Cell lines and reagents
Several common human gastric adenocarcinoma cell lines
[(BGC823), (SGC7901), (MKN45), (MKN28), (AGS)] were
obtained from Foleibao Biotechnology Development
Company (Shanghai, China). Cells were cultured in
complete medium [Roswell Park Memorial Institute
1640 medium (Life Technologies, Carlsbad, CA, USA) with
10% fetal bovine serum (Thermo Scientific HyClone,
South Logan, UT, USA)] at 37°C under 5% CO2. Cells
were harvested in the logarithmic growth phase for
use in the experiments described below. Silencing of
XB130 was carried out using small hairpin RNA
(shRNA) as described previously [4]. The sequences were
GCTGAAGATCACACCGATG for XB130-silencing shRNA
and GCCAGCTTAGCACTGACTC for Scramble shRNA,
respectively. Establishment of cell lines transfected with
XB130 shRNA (sh-XB130) was performed as described
previously [4].
Rabbit antibodies for fibronectin and CD44, as well
as mouse antibodies for E-cadherin, vimentin, α-catenin,
β-catenin, XB130 and β-actin were purchased from
Santa Cruz Biotechnology Company (Santa Cruz, CA, USA).
Rabbit antibodies for β-actin, Akt, and p-Akt were purchased
from Cell Signaling Technology Company (Boston, MA,
USA), while a rabbit antibody targeting XB130 was obtained
from PradoWalnut Company (Walnut, CA, USA).
Fluorescence quantitative real-time polymerase chain
reaction (RT-PCR)
Primer sequences for human XB130 were (F) 5′-AAG
CAGCAGCTCTGATGAGG-3′ and (R) 5′-GGTCTGG
AAGGCTCTTCTGA-3′. Total RNA was extracted
from cultured cells using a Trizol kit (Life Technologies,
Carlsbad, CA, USA). Then cDNA was synthesized using
total RNA and MMLV-RT reverse transcriptase (ProSpec,East Brunswick, NJ, USA). The reaction mixture for
RT-PCR was prepared according to the manufacturer’s
protocol.
Western blotting
Cells were lysed on ice in RIPA buffer [50 mM Tris-Cl
(pH 7.5), 120 mM NaCl, 10 mM NaF, 10 mM sodium
pyrophosphate, 2 mM EDTA, 1 mM Na3VO4, 1 mM
PMSF, and 1% NP-40] containing a protease inhibitor
cocktail (Roche, Basel, CH). The protein content of the
lysates was determined by the method of Bradford.
Approximately 50–75 μg of protein was resolved by
8% or 12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis and was transferred to nitrocellulose
membranes (Millipore, Bedford, MA, USA). The mem-
branes were blocked in TBST [25 mM Tris–HCl (pH 7.5),
125 mM NaCl, and 0.1% Tween 20] containing 5%
bovine serum albumin (BSA), and then incubated
with primary antibodies targeting XB130, E-cadherin,
α-catenin, β-catenin, fibronectin, MMP9, MMP2, vimentin,
CD44, Akt, p-Akt, or β-actin in TBST containing 1% BSA
overnight at 4°C. Subsequently, incubation was done with
the appropriate secondary antibodies for 1 h at room
temperature. Reactive protein bands were visualized with a
Western Lightning Plus-ECL (Perkin Elmer, Waltham,
MA, USA) after exposure to radiographic film and were
quantified with QuantityOne v4.6.2 imaging software
(Bio-Rad, Hercules, CA, USA).
Clonogenic assay
To investigate the ability of cells to form colonies,
1×103 cells transfected with XB130 shRNA or Scramble
RNA were seeded into 6-well plates and incubated for
2 weeks with a medium change every 3–4 days. Colonies
were stained with 0.05% crystal violet (Sigma Chemical
Company, Louis, MO, USA) for 1 h at room temperature,
washed twice with phosphate-buffered saline (PBS), and
observed under a microscope (Olympus, Tokyo, Japan).
Soft agar colony-forming assay
Cells were trypsinized and suspended in 2 mL of
complete medium with 0.3% agar (Sigma Chemical
Company, Louis, MO, USA), and then the agar-cell mixture
was plated onto the bottom layer with 1% agar in complete
medium. After being cultured in an incubator for 4 weeks,
cells were observed and photographed under a microscope.
Cell viability assay
After trypsinization, cells were seeded into 96-well plates at
a density of 0.2×104/well for culture, and cell proliferation
was measured by the methyl thiazolyl tetrazolium (MTT)
assay on days 1, 3, 5, and 7. Briefly, 0.02 mL of MTT
solution (5 mg/mL in PBS) was added to each well and
incubation was performed for 4 h at 37°C, after which the
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and incubation was done for 10 min. Then the optical
density was measured at 492 nm with a Microplate spec-
trophotometer (Thermo Scientific, Pittsburgh, PA, USA).
Cell cycle analysis
Cell cycle analysis was performed by flow cytometry
(Beckman-coulter, Fullerton, CA, USA) after staining
the cells with propidium iodide (PI) (Sigma Chemical
Company, Louis, MO, USA). Cells were harvested by
trypsinization, washed with PBS, and fixed in 70% ethanol
for 30 min on ice. Then the cells were washed again,
resuspended in PBS containing Triton-X-100 and 2 mg/mL
RNase A (Thermo Scientific, Pittsburgh, PA, USA), and
incubated at 37°C for 30 min. Next, PI was added at a final
concentration of 25 μg/mL and the cells were incubated on
ice for 30 min. After staining with PI had been completed,
a minimum of 10,000 events were counted for each sample
by flow cytometry and the cell cycle profile was analyzed
with Flowjo software (TreeStar, Ashland, Oregon, USA).
BrdU incorporation assay
The effect of XB130 inhibition on DNA synthesis was
determined by estimating the uptake of 5-bromo-2′
deoxyuridine-5′monophophate (BrdU) into DNA. Cells
in the logarithmic growth phase were trypsinized, trans-
ferred to a sterile coverslip, and incubated until they
became adherent. After serum starvation for 48 h and
incubation in complete medium for 4 h, the cells were
labeled with 10 μmol/L BrdU for 1 h. Then the cells
were fixed and permeablilized with 0.1% Triton and
0.1% citric acid for 10 min at room temperature, after
which endogenous peroxidase was blocked by incubation
with 3% hydrogen peroxide (H2O2) for 10 min at room
temperature. For nuclear staining, cells were incubated
in serum-free medium with anti-BrdU antibody for
1 h at 37°C. Each experiment was repeated 3 times
independently, and stained cells were counted under
a fluorescence microscope (Olympus, Tokyo, Japan).
Wound healing assay
SGC7901 and MNK45 cells were seeded into 6-well
plates at 90% confluence and incubated overnight for
adherence. Then a wound was made along the center of
each well by scratching the cell layer with the tip of a
200 μL pipette. Next, the wells were washed twice with
PBS to remove loose cells and fresh medium was added.
Photographs were taken at 0 h, 10 h, and 24 h to assess
cell migration into the wound.
Transwell invasion assay
The invasive potential of wild-type and XB130-silenced
GC cells was assessed by an invasion assay using 24-well
Matrigel invasion chambers (BD Biosciences, San Jose,CA, USA). Briefly, Matrigel inserts and an equal number
of control inserts were prepared according to the manu-
facturer’s protocol. SGC7901 cells and MNK45 cells
(5×104/mL in 0.5 mL of serum-free medium) were
added to the upper chambers, and 0.75 mL of medium
supplemented with 5% fetal bovine serum was added to
each of the lower chambers as a chemoattractant. After
incubation for 22 h, the cells remaining in the upper
chambers were removed by scraping, and the invading
cells in the lower chambers were fixed with 3.7%
paraformaldehyde. Then the cells were washed twice
with PBS, stained with hematoxylin for 1 h at room
temperature, and photographed under a microscope.
3D Culture in matrigel
Twenty-four–well dishes were coated with 100 μL of
growth factor reduced solidified Matrigel (BD Biosciences,
San Jose, CA, USA) and placed in an incubator. The cells
were trypsinized and were seeded at a density of 500 per
well in 500 μL of medium. After incubation for 2 weeks,
the cultures were photographed under a microscope.
Immunofluorescence
Cells were grown on coverslips, fixed with 4% parafor-
maldehyde for 30 min, and washed three times with
PBS. Then the cells were permeabilized with 0.2% Triton
X-100 for 5 min at room temperature and blocked with
1% BSA for 1 h. Next, incubation was done with primary
antibodies targeting XB130, E-cadherin, and vimentin
overnight at 4°C, followed by incubation with appropriate
secondary antibodies (Alexa Fluor® 594 or Alexa Fluor® 488)
for 1 h at room temperature. Nuclei were counterstained
with 4′,6-diamidino-2-phenylindole (Life Technologies,
Carlsbad, CA, USA), while F-actin filaments were stained
with rhodamine phalloidin (Sigma Chemical Company,
Louis, MO, USA), and the cells were viewed with a confocal
laser-scanning microscope.
Xenograft model in nude mice
Six-week-old Balb/c nude mice were purchased from Sun
Yat-Sen University (Guangzhou, China). All experimental
procedures involving animals were done in accordance
with the Guide for the Care and Use of Laboratory
Animals and conformed to our institutional ethical
guidelines for animal experiments. ShXB130-transfected,
empty plasmid-transfected, and untransfected SGC7901
cells were trypsinized, collected by centrifugation, and sus-
pended in RPMI-1640 medium. Then 0.2 mL of medium
containing 1×107 cells was injected subcutaneously into
the left and right posterior flank regions of each mouse.
The mice were housed in a pathogen-free environment
and tumor growth was monitored every 3 days. Mice were
killed after 21 days and the volume of each tumor was
calculated according to the formula V = a×b×(a + b)/2,
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of the tumor measured with a sliding caliper.
Immunohistochemistry
Sections (4 μm) of the xenograft tumor tissues were
subjected to immunohistochemical staining as follows.
Formalin-fixed and paraffin-embedded tissue sections
were deparaffinized in xylene, rehydrated in a graded
alcohol series, and washed with PBS. Then the sections
were immersed in 10 mmol/L citrate buffer (pH 6.0) and
heated in a microwave for 30 min. After cooling to room
temperature, endogenous peroxidase was blocked by
incubation with 3% H2O2 in methanol. Nonspecific
binding was blocked by incubating the sections with 1%
BSA in a humid chamber for 60 min. Incubation with
the primary antibodies was subsequently performed
overnight at 4°C using antibodies for XB130, E-cadherin,
vimentin, or p-Akt. Then incubation with suitable
secondary antibodies was done in PBS with 0.3% Triton
X-100/5% horse serum albumin for 1 h in a humidified
chamber. Detection was performed with a Dako Envision
System (Dako, Glostrup, Denmark) after slides were
counterstained with hematoxylin. Isotype-matched IgG
(at the same dilution as the primary antibodies) was used
as the negative control.
Statistical analysis
SPSS 13.0 software was employed for statistical analysis.
Results are reported as the mean±SEM. One-way
ANOVA was done with Bonferroni’s multiple comparison
exact probability test, and Student’s t-test was used to
compare continuous variables between two groups.
Statistical significance was accepted at p < 0.05.
Results
Silencing XB130 inhibits proliferation of GC cell lines
Among the 5 common human GC cell lines, we
found that XB130 expression was higher in SGC7901
(a poorly-differentiated cell line) and MKN45 (a well-
differentiated cell line) than in the other cell lines
(Additional file 1: Figure S1A). Accordingly, we chose
these two cell lines for transfection with sh-XB130.
The knockdown effect of sh-XB130 was confirmed by
real-time PCR (Additional file 1: Figure S1B) and Western
blotting (Additional file 1: Figure S1C). Compared with
Scramble shRNA-transfected cells (Scramble cells), colony
formation by sh-XB130-transfected cells (sh-XB130 cells)
was markedly reduced in the plate colony forming assay
(Figure 1A). In addition, the number of colonies that grew
in soft agar was significantly reduced by transfection of
sh-XB130 (p < 0.01) (Figure 1B). When the MTT assay
was used to assess cell viability over a period of 7 days, we
found that viability was significantly lower in sh-XB130
cells than in Scramble cells, indicating that cell viabilitywas suppressed by knockdown of XB130 (Figure 1C). Cell
cycle analysis revealed that sh-XB130 cells were arrested
in G1 phase, accompanied by a significant reduction of
cells in S phase (Figure 2A). The BrdU labeling assay
showed that DNA synthesis was also strongly inhibited in
sh-XB130 cells (Figure 2B). These results indicate that
cell proliferation was remarkably inhibited by silencing
of XB130.
Silencing XB130 inhibits GC cell motility and invasiveness
and alters the phenotype of GC cells
To assess the effect of down-regulation of XB130 on
cell motility, the wound healing assay and Transwell
assay were performed. After knockdown of XB130, we
found that fewer cells migrated to the center of the
wound in the wound healing assay (Figure 3A) or migrated
into the lower chamber in the Transwell assay (p < 0.01)
(Figure 3B). In addition, sh-XB130 cells were relatively
smooth spheroids with few projections, while Scramble
cells and Control cells developed a multipolar invasive
morphology in 3D culture (Figure 3C and Additional file 2:
Figure S2A). We also investigated the cell structure by
staining F-actin filaments. We found that XB130 was
expressed in the F-actin filaments and XB130 knockdown
resulted in GC cells adopting an epithelial-like morphology
(Figure 3D). These findings indicate that the motility of
GC cells was suppressed along with a decrease of invasive
morphologic features after down-regulation of XB130.
Silencing XB130 reduces tumor growth in nude mice
To determine the influence of XB130 on tumor growth
in vivo, a xenograft nude mouse model was used.
Colonies of sh-XB130 cells, Scamble shRNA cells, and
Control SGC7901 cells were prepared. After subcutaneous
injection into nude mice, all three types of cells formed
tumors (Figure 4A). However, tumor growth was much
slower after injection of sh-XB130 cells than after
injection of Control or Scramble cells (Figure 4B).
After 3 weeks, tumor volume was significantly smaller
in the sh-XB130 group than in the Control and Scramble
groups (p < 0.01, Figure 4B and C). These findings indicate
that GC tumor growth was inhibited by downregulation
of XB130.
XB130 activates the PI3K/Akt pathway and alters both
EMT markers and metastasis-associated proteins in GC
To explore the mechanisms underlying the above-
mentioned changes induced by silencing of XB130, we
postulated that its downregulation might influence the
expression of EMT markers and metastasis-associated
proteins via the PI3K/Akt pathway. We found that knock-
down of XB130 decreased the phosphorylation of Akt in
xenograft GC tissues (Figure 4D) and in GC cell lines
(Figure 5A). Immunofluorescence, immunohistochemistry,
Figure 1 Silencing of XB130 inhibited proliferation of both SGC7901 and MNK45 gastric cancer cells. (A) In the plate colony forming
assay, fewer colonies were formed by sh-XB130-transfected (sh-XB130) cells than by scramble shRNA-transfected (Scramble) cells. (B) In soft agar
culture, the number of colonies was significantly smaller for sh-XB130 cells (#p < 0.01 versus Scramble cells, n = 3 plates per group). Magnification:
×200. (C) In the MTT assay, viability of sh-XB130 cells was markedly suppressed in a time-dependent manner. *p < 0.05 and #p < 0.01 versus the
corresponding time for Scramble cells, n = 3 (6 holes for each time point in each group).
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expression of EMT markers. In contrast to the Scramble
group, silencing of XB130 in xenograft GC tissues and
cultured GC cell lines led to higher expression of the
epithelial marker E-cadherin and lower expression of
the mesenchymal marker vimentin (Figure 4D, Figure 5B,
and Additional file 2: Figure S2B). Western blotting
also showed that silencing of XB130 substantially
increased the expression of epithelial markers (E-cadherin,
α-catenin and β-catenin), while causing a significant
decrease in the expression of mesenchymal markers(fibronectin and vimentin) and metastasis-associated
proteins (MMP2, MMP9 and CD44) (Figure 5C and D).Discussion
The present study has provided the first evidence
concerning the role of XB130 in GC, showing that (1)
XB130 contributes to GC cell proliferation and invasive-
ness, (2) XB130 is involved in phosphorylation of Akt and
EMT-like changes, and (3) XB130 could be a potential
therapeutic target in patients with GC.
Figure 2 XB130 knockdown inhibited cell cycle progression and DNA synthesis by GC cells. (A) XB130 silencing arrested cell cycle
progression in both cell lines, as indicated by accumulation of cells in G1 phase and reduced progression into S phase. Cell cycle analysis was
performed by flow cytometry using propidium iodide staining. (#p < 0.01 versus Scramble cells, n = 3). (B) The BrdU uptake assay showed a
decrease of DNA synthesis in sh-XB130 transfected cells (newly synthesized DNA is stained red by BrdU, while nuclei are stained blue by
4′, 6-diamidino-2-phenylindole). *p < 0.05 and #p < 0.01 versus Scramble cells (n = 3 per group).
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filament-associated protein (AFAP-110) [1], which has
been suggested to have a role in mechanotransduction,
stress fiber stabilization, focal adhesion formation, and
podosome dynamics [15-17]. Regarding the functional
properties of XB130, similar to AFAP-110, it is associated
with regulation of the cytoskeleton, exhibits a high affinity
for lamellipodial F-actin, and influences the motility and
invasiveness of thyroid tumor cells [5]. Consequently,
knockdown of XB130 in thyroid cancer cells decreasesthe wound closure rate, inhibits cell invasion, reduces
lamellipodial persistence, and slows cell spreading [5].
Consistent with that report, we found that silencing of
XB130 decreased the motility of GC cells along with
significant inhibition of the transition from epithelial-like
to fibroblast-like morphology, indicating that XB130
affects the motility and invasiveness of these tumor cells
by interfering with an EMT-like process.
The EMT is a highly conserved process that has been
well characterized in embryogenesis. In epithelial tumors,
Figure 3 Silencing of XB130 inhibited migration and invasion of SGC7901 cells and MNK45 cells, and inhibited the phentotypic
transition. (A) Cell migration was assessed by the wound healing assay. The residual wound was much wider in the sh-XB130 group than in the
Scramble group at 24 hours. (B) In the Transwell migration assay, the number of cells migrating into the lower chamber was much smaller in the
sh-XB130 group than in the Scramble group. (#p < 0.01 versus the Scramble group, n = 3). (C) Matrigel 3D culture was performed to assess cell
morphology. Aggressive protrusions were seen in both the Control group and the Scramble group. In contrast, the invasiveness of sh-XB130
transfected cells was much lower and the cells were round spheroids with few or no protrusions. Scale bar = 100 μm. Similar results were obtained
with both SGC7901 cells and MNK45 cells. (D) SGC7901 cells were immunostained with an XB130 antibody and F-actin filaments were counterstained
using rhodamine phalloidin, while the nuclei were stained with 4′,6-diamidino-2-phenylindole. All experiments were repeated 3 times.
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to become mesenchymal-like cells which is similar to
fibroblasts [18,19]. These changes lead to loss of polarity
for epithelial cells and resulted in promotion of tumor cell
metastasis [6]. However, tumor cells seldom exhibit a
complete change from an epithelial to mesenchymalphenotype (as occurs in the embryological setting),
but rather show more plastic and dynamic changes
that are better classified as “EMT-like” or as a partial
EMT [20,21]. Such EMT-like changes have been re-
ported to be important in the metastasis of epithelial
tumors [22].
Figure 4 XB130 silencing reduced the growth of xenograft tumors. SGC7901 cells were implanted in nude mice by subcutaneous injection
into the anterior right flank, while the same amounts of wild-type, Scramble RNA-transfected, or sh-XB130-transfected SGC7901 cells were injected
into the posterior left and right flanks. (A) After subcutaneous injection, tumors always formed, as shown in this representative picture taken on
day 21. (B) Growth curves of the tumors. Tumor volumes were measured over 21 days in each group. n = 5 per group, *p < 0.05 and #p < 0.01.
(C) Tumors harvested from the three groups on day 21. (D) Representative images of immunostaining for XB130, E-cadherin, vimentin, and p-Akt
in xenograft tumors. Scale bar = 100 μm. n = 3 in each group.
Shi et al. Journal of Translational Medicine 2014, 12:1 Page 8 of 11
http://www.translational-medicine.com/content/12/1/1In most cases, downregulation of E-cadherin seems
to be the final common pathway of the EMT. Epithelial
cells undergoing the EMT tend to develop a spindle-shaped
or fibroblast-like morphology, and display increased
or new expression of mesenchymal markers, including
vimentin and fibronectin [23]. E-cadherin is a cell adhesion
molecule that is anchored to the actin cytoskeleton
via a complex consisting of α-catenin and β-catenin[24], and it is thought to be the key molecule in the
establishment of cell-cell adhesion at adherens junctions.
Fibronectin and vimentin are generally considered to
be typical mesenchymal markers have been reported
to contribute to invasion and distant metastasis of GC
[25-27]. In the present study, expression of E-cadherin
was significantly increased by XB130 knockdown in vivo
and in vitro, while vimentin expression was partially
Figure 5 Silencing of XB130 modulated phosphorylation of Akt and expression of EMT-associated proteins by cultured GC cell lines.
(A) Phosphorylation of Akt was significantly decreased by XB130 knockdown. (B) Immunostaining for E-cadherin and vimentin. E-cadherin was
significantly upregulated and vimentin was downregulated by XB130 knockdown. Scale bar = 50 μm. n = 3 in each group. (C) Representative
results of Western blotting. In comparison with the Scramble group, silencing of XB130 upregulated the expression of E-cadherin, α-catenin and
β-catenin, while it downregulated expression of fibronectin, vimentin, CD44, MMP9 and MMP2. (D) Quantitative analysis of panel C. #p < 0.01
versus the Scramble group, n = 3. Ctrl = control, Scr = Scramble, Sh = sh-XB130.
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EMT-like changes of GC.
The PI3K/Akt signaling pathway has been reported to
be influenced by XB130 [10,11], and phosphorylation of
Akt promotes EMT-like changes through repression of
Snail-mediated cadherin 1[7]. MMP2 and MMP9 are
members of the matrix metalloproteinase family, which
bind to zinc and act on the extracellular matrix (ECM)
to degrade type IV collagen in the basement membrane.
After basement membrane integrity is lost, metastasisoccurs and the survival rate decreases dramatically in
GC patients [28-30]. CD44 is recognized as a marker of
cancer stem cells, which are a small population of
stem-like cells residing in tumor tissues that can cause
tumor formation, recurrence, and metastasis [31]. As a
transmembrane glycoprotein expressed on the cell surface,
CD44 and its variants can bind to the ECM and are
involved in making connections between cells and the
matrix [31]. All of these extracellular factors contribute to
EMT-like changes in tumor cells. In the present study,
Shi et al. Journal of Translational Medicine 2014, 12:1 Page 10 of 11
http://www.translational-medicine.com/content/12/1/1we found that phosphorylation of Akt, expression of
matrix metalloptoteinases, and expression of cancer
stem cell markers were all significantly suppressed by
XB130 knockdown, further confirming that XB130
may enhance the EMT-like process and promote the
motility and invasiveness of GC cells.
As an adaptor protein, XB130 promoted GC cell
proliferation and migration, while knockdown of
XB130 contributed to reduced growth of xenograft
tumors, suggesting that XB130 is an oncoprotein in
GC. It may seem paradoxical that our previous study
demonstrated a positive correlation between expression of
XB130 and the prognosis [4]. In fact, such discrepancy
is not uncommon for oncogenes. Several oncogenes
are known to be downregulated in tumors and their
low expression predicts a poor prognosis. Clinical
studies have shown that low expression of the oncopro-
teins Bcl-2 and Bcl-B is associated with a poor outcome of
GC [32-34]. A similar “discrepancy” has also been noted
for some tumor suppressor genes. For example, it has
been reported that overexpression of the tumor suppres-
sor gene p53 is significantly correlated with unfavorable
clinicopathologic parameters and lower overall survival
[35]. Moreover, a correlation between gene expression
and the prognosis is not necessarily indicative of a
causal relationship. Compensatory mechanisms may
downregulate some oncogenes and upregulate some
tumor suppressor genes.
In addition, clinical prognosis is influenced by various
factors including gene expression and medical interven-
tions. Currently, fluoropyrimidine derivative-based and
platinum-based combination regimens are accepted as
conventional first-line treatment for GC [36]. In our
previous study [4], 80% of patients were treated with
5-fluorouracil (5-FU), and XB130-negative patients
had a lower survival rate when they received 5-FU. In
addition, sensitivity studies showed that XB130 knock-
down reduces the sensitivity of GC cells to 5-FU [4].
These results indicate that tumors with high levels of
XB130 expression show greater sensitivity to 5-FU,
leading to an improved survival rate, which may be
an explanation for the better prognosis of patients
with high expression of XB130 [4]. Taken together,
these findings suggest that XB130 may be a potential
target for the treatment of GC.Conclusions
In summary, the present study showed that XB130 is an
oncogene that promotes tumor growth and metastasis,
probably through its role in an EMT-like process. XB130
seems to be an important regulator of the metastasis of
gastric cancer and the potential target for treatment of
this cancer.Additional file
Additional file 1: Figure S1. Baseline expression and silencing effect of
XB130 in gastric cancer (GC) cell lines. (A) Baseline expression of XB130 in
various GC cell lines. Knocking down effect of sh-XB130 in SGC7901 and
MKN45 cell lines was evaluated. Real-time PCR (B) and Western blot (C)
revealed that sh-XB130 effectively suppressed the expression of XB130 in
both cell lines.
Additional file 2: Figure S2. Silencing XB130 changed the morphology
of gastric cancer cells and altered the EMT-like associated proteins by
cultured cells. (A) Matrigel 3D culture was performed to assess cell
morphology. Aggressive protrusion-positive structures were found in the
Scramble and Control group. In contrast, the invasiveness of sh-XB130
transfected cells was much lower and the cells were round spheroids
with no or few protrusions. Pictures in upper line showed the view of
2–3 cells in each group under 100× magnification and the others
were graphed under 200× magnification. (500 cells were incubated in
each well). (B) E-cadherin and vimentin immunofluorescence staining.
E-cadherin was significantly upregulated and vimentin was downregulated
by XB130 knockdown. Scale bar = 100 μm. Experiments were repeated
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